Centrul De Oncologie SF Nectarie S.R.L. — Clinical Trial Site

179 Registered trials

72 Currently recruiting

Organisation

Centrul De Oncologie SF Nectarie S.R.L.

Location

Craiova, Romania

Identifier

ORG-100032570

Address

Strada Caracal Nr. 109, 200746, Romania

Departments

040006: Oncology
2301:Oncology
2302:Oncologie Medicala
3201:oncology
3210: Oncology
6101:Oncology
6103: Oncology
734: Oncology
93150005: Oncology
Departament Clinic Oncologie Medicala
Departament Oncologie Medicală
Departamentul Oncologie
Departamentul Oncologie Medicală
Department of Medical Oncology
Medical Oncology
Medical Oncology department
N/A
NA
Omcologie
Oncologie
Oncologie Medicala
Oncology
ROU004: Oncology
Sectia Oncologie Medicala
Specialitatea Oncologie Medicala

Clinical trials at this site (179)

Search interface

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended

2023-503428-24-00 Neoplasms, Head and Neck 4 2024-01-19
Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended

2023-505023-31-00 Renal cell carcinoma 5 2023-11-17
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non- 5 2023-11-01
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com… Ended

2022-501576-25-00 Melanoma 5 2023-07-07
Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended

2022-502145-10-00 Hormone Receptor (HR)-Positive, Human Epidermal Growth 5 2023-06-06
A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastroin… Ended

2023-507522-16-00 Metastatic Esophageal or Gastric Cancer 5 2023-05-22
An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Ended

2022-501463-40-01 Locally Advanced or Metastatic Cholangiocarcinoma 5 2023-05-03
Clinical Study of Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) versus Intravenous Pembrolizumab, Given with Chemoth… Ended

2022-501506-36-00 First-line treatment of participants with metastatic no 5 2023-04-11
Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended

2023-503501-11-00 Metastatic Non-small Cell Lung Cancer 5 2023-02-09
Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U… Ended

2023-505772-30-00 Melanoma 5 2022-11-09
Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended

2023-509429-37-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5 2022-10-03
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable… Ended

2023-504195-14-00 PD-L1-negative metastatic triple-negative breast cancer 5 2022-08-31
Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended

2023-507933-12-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 5 2022-08-18
Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended

2023-503517-30-00 Extensive-stage small-cell lung cancer 5 2022-04-01
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended

2023-506241-30-00 Advanced Colorectal Cancer with KRAS G12C Mutation 5 2021-11-30
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance… Ended

2023-509133-39-00 Hormone receptor positive, HER2-negative advanced breas 5 2021-11-29
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gas… Ended

2023-510319-20-00 Gastroesophageal Adenocarcinoma (GEA) 5 2021-10-21
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lun… Ended

2023-507494-18-00 Non-small cell lung cancer with ROS proto-oncogene 1, r 5 2021-09-24
Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or A… Ended

2023-507963-20-00 Metastatic Gastric Adenocarcinoma 5 2021-08-19
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic… Ended

2023-506752-24-00 Locally recurrent inoperable or metastatic HR+/HER2- br 5 2021-08-05
Study of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Given with Chemotherapy, to Treat Metastatic Squamous or Non Squamous … Ended

2023-508308-40-00 Metastatic (stage IV) squamous or nonsquamous non-small 5 2021-07-30
A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended

2022-502100-70-00 Participants with Microsatellite Instability-High (MSI- 10 2021-06-23